Valion Bio, Inc.
VBIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001787740
No open-market purchases or sales by Valion Bio, Inc. insiders were filed in the last 90 days; 13 institutions reported holding it in 13F filings for Q2 2026, worth $205.6K in total; no superinvestor holds it.
13F holders, Q2 2023
Institutional positions in Valion Bio, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 12
- 0 vs. Q1 2023
- Shares held
- 914.7K
- −513.2K (−35.9%) vs. Q1 2023
- Total value
- $96.3K
- −$119.3K (−55.3%) vs. Q1 2023
- New holders
- 3
- 3 more added
- Sold out
- 3
- 4 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VBIO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 13 | $205.6K |
| Q1 2026 | 9 | $233.4K |
| Q4 2025 | 7 | $118.8K |
| Q3 2025 | 7 | $567.1K |
| Q2 2025 | 4 | $186.6K |
| Q1 2025 | 2 | $54 |
| Q4 2024 | 9 | $90.7K |
| Q3 2024 | 10 | $69.8K |
| Q2 2024 | 10 | $240.6K |
| Q1 2024 | 5 | $83.8K |
| Q4 2023 | 7 | $112.0K |
| Q3 2023 | 6 | $31.7K |
| Q2 2023 | 12 | $96.3K |
| Q1 2023 | 12 | $215.6K |
| Q4 2022 | 7 | $43.4K |
| Q3 2022 | 4 | $30.0K |
| Q2 2022 | 5 | $104.0K |
| Q1 2022 | 7 | $329.0K |
| Q4 2021 | 9 | $492.0K |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Valion Bio, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sheets Smith Wealth Management | 600,000 | $63.8K | 0.01% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 96,821 | $10.3K | 0.00% | +96,821 | New |
| Boothbay Fund Management, LLC | 34,200 | $3.62K | 0.00% | +4,200+14.0% | Added |
| Millennium Management LLC | 30,192 | $3.20K | 0.00% | +30,192 | New |
| UBS Group AG | 29,619 | $3.14K | 0.00% | −103,241−77.7% | Reduced |
| Susquehanna International Group, LLP | 29,138 | $3.09K | 0.00% | +16,351+127.9% | Added |
| Cubist Systematic Strategies, LLC | 28,587 | $3.03K | 0.00% | +28,587 | New |
| One68 Global Capital, LLC | 19,100 | $2.02K | 0.01% | 00.0% | Unchanged |
| HRT Financial LP | 26,944 | $2.00K | 0.00% | −98−0.4% | Reduced |
| Tower Research Capital LLC (TRC) | 11,054 | $1.17K | 0.00% | −21−0.2% | Reduced |
| Advisor Group Holdings, Inc. | 8,900 | $941 | 0.00% | −5,700−39.0% | Reduced |
| Wells Fargo & Company | 192 | $20 | 0.00% | +146+317.4% | Added |
| Warberg Asset Management LLC | 0 | $0 | 0.00% | −541,618−100.0% | Sold out |
| Ergoteles LLC | 0 | $0 | 0.00% | −28,403−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −10,413−100.0% | Sold out |